Cathay Biotech Stock Gross Profit

688065 Stock   42.84  0.22  0.51%   
Cathay Biotech fundamentals help investors to digest information that contributes to Cathay Biotech's financial success or failures. It also enables traders to predict the movement of Cathay Stock. The fundamental analysis module provides a way to measure Cathay Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cathay Biotech stock.
Last ReportedProjected for Next Year
Gross Profit608.8 M618.3 M
The current year's Gross Profit is expected to grow to about 618.3 M.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cathay Biotech Company Gross Profit Analysis

Cathay Biotech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Cathay Biotech Gross Profit

    
  2.44 B  
Most of Cathay Biotech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cathay Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Cathay Biotech reported 2.44 B of gross profit. This is 84.69% lower than that of the Chemicals sector and 13.16% lower than that of the Materials industry. The gross profit for all China stocks is 91.07% higher than that of the company.

Cathay Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cathay Biotech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cathay Biotech could also be used in its relative valuation, which is a method of valuing Cathay Biotech by comparing valuation metrics of similar companies.
Cathay Biotech is currently under evaluation in gross profit category among its peers.

Cathay Fundamentals

About Cathay Biotech Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cathay Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cathay Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cathay Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Cathay Stock

Cathay Biotech financial ratios help investors to determine whether Cathay Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cathay with respect to the benefits of owning Cathay Biotech security.